HMGB1 cytoplasmic translocation in patients with acute liver failure

BMC Gastroenterology

Volumn 11, Issue , 2011, Pages

  Zhou, Rong Rong ^a   Zhao, Shu Shan ^a,b   Zou, Ming Xiang ^a   Zhang, Pan ^a   Zhang, Bao Xing ^a   Dai, Xia Hong ^a   Li, Ning ^a   Liu, Hong Bo ^a   Wang, Haichao ^c   Fan, Xue Gong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOSAMINE; HIGH MOBILITY GROUP B1 PROTEIN; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ACUTE LIVER FAILURE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEPG2; CHRONIC HEPATITIS; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT; UPREGULATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CASE CONTROL STUDY; CELL LINE; CYTOPLASM; DISEASE MODEL; DRUG EFFECT; LIVER CELL; METABOLISM; PATHOLOGY;

ADULT; ANIMALS; CASE-CONTROL STUDIES; CELL LINE; CYTOKINES; CYTOPLASM; DISEASE MODELS, ANIMAL; FEMALE; HEPATITIS B; HEPATOCYTES; HMGB1 PROTEIN; HUMANS; LIPOPOLYSACCHARIDES; LIVER FAILURE, ACUTE; MALE; MICE; MICE, INBRED BALB C; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952553248     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-11-21     Document Type: Article

References (37)

1. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999, 19:5237-5246. 84367, 10409715.
2. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanoa V, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251. 10.1126/science.285.5425.248, 10398600.
3. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol 2000, 165:2950-2954.
4. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195. 10.1038/nature00858, 12110890.
5. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5:331-342. 10.1038/nri1594, 15803152.
6. Harris HE, Raucci A. Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep 2006, 7:774-778. 1525157, 16858429.
7. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81:1-5. 10.1189/jlb.0306164, 17032697.
8. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003, 101:2652-2660. 10.1182/blood-2002-05-1300, 12456506.
9. Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala HM, Erlandsson-Harris H, Andersson U, Yang H, Tracey KJ, Andersson J, Palmblad JE. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003, 254:375-385. 10.1046/j.1365-2796.2003.01204.x, 12974876.
10. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, Tracey KJ. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000, 192:565-570. 10.1084/jem.192.4.565, 2193240, 10952726.
11. Levy RM, Mollen KP, Prince JM, Kaczorowski DJ, Vallabhaneni R, Liu S, Tracey KJ, Lotze MT, Hackam DJ, Fink MP, Vodovotz Y, Billiar TR. Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol 2007, 293:R1538-1544. 10.1152/ajpregu.00272.2007, 17652366.
12. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, Lee ML, Andersson J, Tokics L, Treutiger CJ. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005, 33:564-573. 10.1097/01.CCM.0000155991.88802.4D, 15753748.
13. Gibot S, Massin F, Cravoisy A, Barraud D, Nace L, Levy B, Bollaert PE. High-mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med 2007, 33:1347-1353. 10.1007/s00134-007-0691-2, 17525840.
14. Angus DC, Yang L, Kong L, Kellum JA, Delude RL, Tracey KJ, Weissfeld L. Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med 2007, 35:1061-1067. 10.1097/01.CCM.0000259534.68873.2A, 17334246.
15. Yasuda T, Ueda T, Takeyama Y, Shinzeki M, Sawa H, Nakajima T, Ajiki T, Fujino Y, Suzuki Y, Kuroda Y. Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis. Pancreas 2006, 33:359-363. 10.1097/01.mpa.0000236741.15477.8b, 17079940.
16. Goldstein RS, Gallowitsch-Puerta M, Yang L, Rosas-Ballina M, Huston JM, Czura CJ, Lee DC, Ward MF, Bruchfeld AN, Wang H, Lesser ML, Church AL, Litroff AH, Sama AE, Tracey KJ. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 2006, 25:571-574. 10.1097/01.shk.0000209540.99176.72, 16721263.
17. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005, 41:1179-1197. 10.1002/hep.20703, 15841455.
18. Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009, 49:S13-21. 10.1002/hep.22881, 2809016, 19399811.
19. Lee WM. Etiologies of acute liver failure. Semin Liver Dis 2008, 28:142-152. 10.1055/s-2008-1073114, 18452114.
20. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000, 32:734-739. 10.1053/jhep.2000.17687, 11003617.
21. Boermeester MA, Houdijk AP, Meyer S, Cuesta MA, Appelmelk BJ, Wesdorp RI, Hack CE, Van Leeuwen PA. Liver failure induces a systemic inflammatory response. Prevention by recombinant N-terminal bactericidal/permeability-increasing protein. Am J Pathol 1995, 147:1428-1440. 1869528, 7485405.
22. Muto Y, Nouri-Aria KT, Meager A, Alexander GJ, Eddleston AL, Williams R. Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 1988, 2:72-74. 10.1016/S0140-6736(88)90006-2, 2898700.
23. Wu Z, Han M, Chen T, Yan W, Ning Q. Acute liver failure: mechanisms of immune-mediated liver injury. Liver Int 2010, 30:782-794. 10.1111/j.1478-3231.2010.02262.x, 20492514.
24. Sha Y, Zmijewski J, Xu Z, Abraham E. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 2008, 180:2531-2537.
25. Ando K, Moriyama T, Guidotti LG, Wirth S, Schreiber RD, Schlicht HJ, Huang SN, Chisari FV. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 1993, 178:1541-1554. 10.1084/jem.178.5.1541, 2191233, 8228807.
26. Streetz K, Leifeld L, Grundmann D, Ramakers J, Eckert K, Spengler U, Brenner D, Manns M, Trautwein C. Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology 2000, 119:446-460. 10.1053/gast.2000.9364, 10930380.
27. Sitia G, Iannacone M, Muller S, Bianchi ME, Guidotti LG. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol 2007, 81:100-107. 10.1189/jlb.0306173, 16935945.
28. Morikawa A, Sugiyama T, Kato Y, Koide N, Jiang GZ, Takahashi K, Tamada Y, Yokochi T. Apoptotic cell death in the response of D-galactosamine-sensitized mice to lipopolysaccharide as an experimental endotoxic shock model. Infect Immun 1996, 64:734-738. 173830, 8641774.
29. Le MK, Klemm K, Abshagen K, Eipel C, Menger MD, Vollmar B. Attenuation of inflammation and apoptosis by pre- and posttreatment of darbepoetin-alpha in acute liver failure of mice. Am J Pathol 2007, 170:1954-1963. 10.2353/ajpath.2007.061056, 1899440, 17525263.
30. Feng B, Wu SM, Lv S, Liu F, Chen HS, Gao Y, Dong FT, Wei L. A novel scoring system for prognostic prediction in d-galactosamine/lipopolysaccharide-induced fulminant hepatic failure BALB/c mice. BMC Gastroenterol 2009, 9:99. 10.1186/1471-230X-9-99, 2808305, 20040118.
31. Leifeld L, Dumoulin FL, Purr I, Janberg K, Trautwein C, Wolff M, Manns MP, Sauerbruch T, Spengler U. Early up-regulation of chemokine expression in fulminant hepatic failure. J Pathol 2003, 199:335-344. 10.1002/path.1298, 12579535.
32. Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, Tracey KJ. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999, 126:389-392. 10.1016/S0039-6060(99)70182-0, 10455911.
33. Liu S, Stolz DB, Sappington PL, Macias CA, Killeen ME, Tenhunen JJ, Delude RL, Fink MP. HMGB1 is secreted by immunostimulated enterocytes and contributes to cytomix-induced hyperpermeability of Caco-2 monolayers. Am J Physiol Cell Physiol 2006, 290:C990-999. 10.1152/ajpcell.00308.2005, 16282196.
34. Takano K, Shinoda M, Tanabe M, Miyasho T, Yamada S, Ono S, Masugi Y, Suda K, Fukunaga K, Hayashida T, Hibi T, Obara H, Takeuchi H, Kawachi S, Kawasako K, Okamoto M, Yokota H, Maruyama I, Kitagawa Y. Protective Effect of High-Mobility Group Box 1 Blockade on Acute Liver Failure in Rats. Shock 2010, 34:573-579. 10.1097/SHK.0b013e3181df0433, 20351624.
35. Fontana RJ. Acute liver failure due to drugs. Semin Liver Dis 2008, 28:175-187. 10.1055/s-2008-1073117, 18452117.
36. Yin XM, Ding WX. Death receptor activation-induced hepatocyte apoptosis and liver injury. Curr Mol Med 2003, 3:491-508. 10.2174/1566524033479555, 14527081.
37. Torisu T, Nakaya M, Watanabe S, Hashimoto M, Yoshida H, Chinen T, Yoshida R, Okamoto F, Hanada T, Torisu K, Takaesu G, Kobayashi T, Yasukawa H, Yoshimura A. Suppressor of cytokine signaling 1 protects mice against concanavalin A-induced hepatitis by inhibiting apoptosis. Hepatology 2008, 47:1644-1654. 10.1002/hep.22214, 18393318.